TO THE EDITOR
MDS is a relatively rare hematological malignant disease that occurs in childhood and adolescence. The ultimate survival rate is very poor due to bone marrow failure or severe infections and the most effective curative therapy is allogeneic bone marrow transplantation (BMT). However, the number of patients with an available BMT donor is limited. In hypoplastic MDS, it is generally difficult to evaluate the therapeutic efficacy by objective methods other than clinical symptoms such as the frequencies of bleeding episodes, transfusions or infections. Here we report an adolescent case of MDS with 8 trisomy that was successfully treated by LD-AraC + rhG-CSF and unrelated BMT (U-BMT). The clinical course was evaluated using fluorescence in situ hybridization (FISH) analysis. A 16-year-old girl was diagnosed with MDS(RA) in January 1993. On admission, the karyotype of bone marrow (BM) cells was 47, XX, +8. She was treated with ubenimex and rhG-CSF. However, her pancytopenia and bleeding tendency worsened and platelet transfusions were required every day. This therapy was discontinued and LD-AraC + rhG-CSF was started. The time schedule of this therapy was as follows; AraC 10 mg/day (intravenous infusion) for 5 days, rhG-CSF 100 g/day for 21 days. Later in the clinical course, oral administration of cytarabine ocfosfate, 100 mg/day for 7 days, was substituted for AraC. This therapy was started in August 1993 and was repeated every 4 weeks until U-BMT. In parallel with this therapy, we performed FISH analysis with a D8Z1 probe on her peripheral blood(PB). This probe detected the centromere of chromosome 8 and 8 trisomy cloned cells showed three signals (Figure 1) . We sequentially performed this analysis for disease monitoring after initiation of LD-AraC + rhG-CSF therapy and the percentages of 8 trisomy clones were calculated. As shown in Table 1 , more than 75% of her PB was occupied by 8 trisomy clones at the initiation of LDAraC + rhG-CSF therapy. However, after one course of therapy, 8 trisomy clone markedly decreased to 32.6%. This therapy was continued and 8 trisomy clones gradually decreased to 7.4% in July 1994. Positive percentages were maintained at about 10%. We also analyzed BM cells by FISH several times and the results were almost the same as those in PB. Although she exhibited massive intra-cranial hemorrhage in September 1993, the bleeding tendency gradually improved. She remained transfusion dependent, however, platelet transfusions decreased to twice a week. No severe infections were observed throughout the clinical course. Finally, she received U-BMT in August 1995. The patient has remained well and free of disease for 39 months after BMT.
LD-AraC is usually used for adult cases of MDS or elderly acute myeloblastic leukemia patients.
1-3 rhG-CSF is also used for MDS patients 4,5 and granulocyte-macrophage colony-stimulating factor (GM-CSF) is used as a cytokine combined LDAraC. 6, 7 In a previous study, GM-CSF plus LD-AraC was reported to be more effective than GM-CSF alone. 6 Therefore, our LD-AraC + rhG-CSF therapy may be useful for MDS therapy. Although it is controversial whether the effect of LD-AraC is associated with differentiation induction or cytotoxicity, Mittermü ller et al 8 reported that LD-AraC acted cytotoxically rather than by inducing differentiation. Gerhartz et al 7 also reported the cytotoxic effect of LD-AraC. Our observation further supports their findings. In the clinical course of this patient, sequential FISH analysis was very informative for disease monitoring. Hotta et al 9 reported the clinical efficacy of LD-AraC evaluated by conventional cytogenetic analysis and clonal culture. FISH analysis is also useful for quantitative assay of abnoramal clones although the available probes are limited.
Our results showed the therapeutic efficacy of LD-AraC + rhG-CSF for MDS at least as the maintenance therapy until BMT. Our observation was limited to a single case and further large-scale studies are needed to confirm our findings. Are we ready to curtail testing for TEL/AML1 fusion?
A Kikuchi

TO THE EDITOR
In a recent issue of Leukemia, Borowitz et al 1 have shown a significant correlation between surface expression of two Blineage antigens and rearrangements of the TEL gene in children with acute lymphoblastic leukemia (ALL). This lead authors to suggest that the patients who are screened by immunophenotypic features as TEL/AML1 negative may not be tested for TEL/AML1 fusion by reverse-transcriptase polymerase chain reaction (RT-PCR). Borowitz et al present new data that are important for studying biologic behavior of blasts with this favorable molecular genetic feature. However, we feel that the suggestion of using immunophenotypic features as a cost-effective pre-screening of patients predicted for TEL/AML1 negativity needs re-evaluation.
TEL/AML1-positive ALL is a clinically important subgroup of pediatric ALL. The patients with this chromosomal fusion account for 20 to 25% of children with ALL in the developed world.
2 Several prospective and retrospective studies have documented good prognosis for these patients.
3,4 The majority of patients with TEL/AML1-positive ALL tend to cluster around the modus of the pre-school peak age; however, not the entire peak is formed by these patients. 5 Several studies reported that TEL/AML1-positive ALL are likely to express myeloid antigens CD13 and CD33. 2, 6, 7 Later, lack of expression of a granulocytic antigen KOR-SA3544 has been shown to predict TEL/AML1 negativity. 7 This antigen is up to now the most reliable predictor of TEL/AML1 negativity (Table 1) . Borowitz et al now add a combination of CD20 and CD9 to the list of antigens with a predictive value for TEL rearrangement (and hence for TEL/AML1 status). In addition to immunophenotypic features, hyperdiploidy is known to inversely correlate with the TEL/AML1 positivity.
1,2,6 Thus, TEL/AML1-positive ALL emerges as a disease with distinct clinical and immunophenotypic features. However, as Borowitz et al noted, none of the features predicts TEL/AML1 status in all patients (we have recently observed a TEL/AML1-positive patient with 12% KOR-SA3544-positive blasts at diagnosis thus proving that even this test has a negative predictive value less than 100%, Table 1 ).
What are the requirements for a pre-screening test for TEL/AML1 testing? Ultimate proof of a clinical usefulness would obviously be a requirement if the result of a predictive test per se has a high prognostic value for treatment outcome. Thus far, this has not been documented for any of the immunophenotypic features listed in Table 1 . To the contrary, CD13 and CD33 have been shown to have no clinical impact in large cohorts. 8 The criteria for a pre-screening method would be: (1) high and reproducible negative predictive value; and (2) low cost and labor intensity of the method when compared to RT-PCR for TEL/AML1. The first of the two criteria is not successfully met by any of the immunophenotypes: while CD13 and CD33 do not have a very high negative predictive value, KOR-SA3544 antigen as well as combination of CD9 and CD20 have been only reported from single studies. Although we observed a tendency of CD20-positive cases to
